The SARS-CoV-2 proteome shares regions of conservation with endemic human
coronaviruses (CoVs), but it remains unknown to what extent these may be cross …

A major goal of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccine efforts is to elicit antibody responses that confer protection. Mapping the epitope …

INTRODUCTION A systematic characterization of the humoral response to severe acute
respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed. This …

The search for potential antibody-based diagnostics, vaccines, and therapeutics for
pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused …

SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has
resulted in millions of deaths worldwide. Novel coronavirus infections in humans have …

Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity
induced by natural infection and vaccination. We assessed the recognition of three VOCs (B …

The spillover of animal coronaviruses (aCoVs) to humans has caused SARS, MERS, and
COVID-19. Although antibody responses displaying cross-reactivity between SARS-CoV-2 …

Abstract As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to
spread, characterization of its antibody epitopes, emerging strains, related coronaviruses …

Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing
question for public health and for vaccine development. We developed highly sensitive …

Preexisting cross-reactivity to SARS-CoV-2 occurs in the absence of prior viral exposure.
However, this has been difficult to quantify at the population level due to a lack of reliably …